Search results for:
insulin aspart
insulin aspart
Drug Name |
Form |
Strength |
Formulary Unrestricted |
Formulary Restricted |
Non-Formulary |
Interchange |
Fiasp |
DEVICE, SUBCUTANEOUS |
100 units/mL |
|
|
|
|
Merilog |
INJECTION, SUBCUTANEOUS |
100 units/mL |
|
|
|
|
NovoLOG |
SOLUTION, SUBCUTANEOUS |
100 units/mL |
|
|
|
|
Last updated: Jun. 30, 2025
NovoLOG and Fiasp are approved for sample use in HH Endocrinology and Diabetes Clinics.
Approved to round DOWN to nearest whole unit if calculations result in dose in fractions.
NovoLOG is interchanged to HumaLOG on a unit per unit basis.
Fiasp is interchanged to HumaLOG on a unit per unit basis.
Merilog is interchanged to HumaLOG on a unit per unit basis.
Patients with orders for the hospital’s adult sliding scale insulin order set have orders to implement the hospital’s hypoglycemia orders. However, some patients have orders for scheduled or PRN insulin without use of the sliding scale insulin order set. These patients may not have PRN orders for treatment of hypoglycemia.
To improve safety with insulin use, the following policy has been approved by the P&T Committee:
Reviewed: 27 March 2018 (Fiasp) June 2025 (Merilog)